Shares of Adamas Pharmaceuticals Inc. (NASDAQ:ADMS) were up 7% during mid-day trading on Wednesday . The stock traded as high as $13.90 and last traded at $13.90, with a volume of 171,285 shares. The stock had previously closed at $12.99.

Several analysts have recently issued reports on ADMS shares. Needham & Company LLC reiterated a “buy” rating and issued a $38.00 target price on shares of Adamas Pharmaceuticals in a research note on Wednesday, July 20th. Noble Financial reiterated a “buy” rating and issued a $25.00 target price on shares of Adamas Pharmaceuticals in a research note on Tuesday, June 28th. Credit Suisse Group AG restated a “buy” rating on shares of Adamas Pharmaceuticals in a research report on Wednesday, June 22nd. Mizuho restated a “buy” rating on shares of Adamas Pharmaceuticals in a research report on Thursday, June 23rd. Finally, JMP Securities restated a “buy” rating on shares of Adamas Pharmaceuticals in a research report on Wednesday, June 15th. Two investment analysts have rated the stock with a sell rating and nine have assigned a buy rating to the stock. Adamas Pharmaceuticals has an average rating of “Buy” and a consensus price target of $32.00.

The company’s 50 day moving average is $14.36 and its 200-day moving average is $15.30. The firm’s market cap is $302.40 million.

A hedge fund recently raised its stake in Adamas Pharmaceuticals stock. Dimensional Fund Advisors LP boosted its stake in shares of Adamas Pharmaceuticals Inc. (NASDAQ:ADMS) by 585.5% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 69,411 shares of the specialty pharmaceutical company’s stock after buying an additional 59,285 shares during the period. Dimensional Fund Advisors LP owned 0.38% of Adamas Pharmaceuticals worth $1,966,000 at the end of the most recent reporting period.

Adamas Pharmaceuticals, Inc is a pharmaceutical company. The Company is focused on the development and commercialization of therapeutics targeting chronic disorders of the central nervous systems (CNS). Its segment focuses on the development and commercialization of therapeutics targeting chronic disorders of the central nervous system.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.